Global C5 Complement Inhibitor Market is projected to reach US$ 298.88 billion by 2033

Global C5 Complement Inhibitor Market was valued at USD 10.2 billion in 2025 and is projected to reach US$ 298.88 billion by 2033, at a CAGR of 16.8% during the forecast period. Global C5 Complement Inhibitor Market focuses on therapies that block the complement protein C5, a key player in immune response and inflammation. These inhibitors, such as eculizumab and raflizumab, are crucial in treating rare conditions like Paroxysmal Nocturnal Hemoglobinuria (PNH) and Atypical Hemolytic Uremic Syndrome (aHUS). Driven by rising chronic disease prevalence, increased R&D, and advancements in biologics, the market is expected to witness steady growth through 2033. Key regions include North America, Europe, and Asia-Pacific, with Alexion Pharmaceuticals as a leading player. However, the market faces challenges like high drug development costs, regulatory hurdles, and patent expirations.
Click for free PDF Sample Report: https://prospectresearchreports.com/report/432532?type=request_sample